Tikvah Therapeutics, Inc. and Apkarian Technologies, LLC of Chicago have announced an agreement relating to Apkarian's patents and patent applications involving NMDA receptor agonists. The patents and applications specifically relate to the treatment of chronic pain and pain-related indications using glycine receptor agonists. Under the agreement, Tikvah receives exclusive rights to the Apkarian
patents and applications. Tikvah, based in Atlanta, focuses on finding new uses for late-stage pharmaceutical compounds in treating central nervous system diseases. Apkarian owns intellectual property developed by Dr. A. Vania Apkarian (at left), a professor at Northwestern University.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments